510 related articles for article (PubMed ID: 10445808)
1. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808
[TBL] [Abstract][Full Text] [Related]
2. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.
Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
[TBL] [Abstract][Full Text] [Related]
4. Different meaning of CD38 molecule expression on CD4+ and CD8+ cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years.
de Martino M; Rossi ME; Azzari C; Gelli MG; Galli L; Vierucci A
Pediatr Res; 1998 Jun; 43(6):752-8. PubMed ID: 9621984
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children.
Paul ME; Shearer WT; Kozinetz CA; Lewis DE
J Allergy Clin Immunol; 2001 Aug; 108(2):258-64. PubMed ID: 11496243
[TBL] [Abstract][Full Text] [Related]
6. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
7. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
[TBL] [Abstract][Full Text] [Related]
8. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
Choremi-Papadopoulou H; Tsalimalma K; Dafni U; Dimitracopoulou A; Kordossis T
J Med Virol; 2004 Jun; 73(2):235-43. PubMed ID: 15122798
[TBL] [Abstract][Full Text] [Related]
9. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
[TBL] [Abstract][Full Text] [Related]
10. Cd4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection.
Hengel RL; Jones BM; Kennedy MS; Hubbard MR; McDougal JS
J Infect Dis; 2001 Jul; 184(1):93-7. PubMed ID: 11398115
[TBL] [Abstract][Full Text] [Related]
11. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.
Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT
Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418
[TBL] [Abstract][Full Text] [Related]
13. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.
Kestens L; Vanham G; Vereecken C; Vandenbruaene M; Vercauteren G; Colebunders RL; Gigase PL
Clin Exp Immunol; 1994 Mar; 95(3):436-41. PubMed ID: 7907956
[TBL] [Abstract][Full Text] [Related]
14. [T-lymphocyte immune in HIV-infected people and AIDS patients in China].
Li T; Qiu Z; Wang A; Sheng R
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1391-5. PubMed ID: 12509921
[TBL] [Abstract][Full Text] [Related]
15. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1.
Bouscarat F; Levacher-Clergeot M; Dazza MC; Strauss KW; Girard PM; Ruggeri C; Sinet M
AIDS Res Hum Retroviruses; 1996 Jan; 12(1):17-24. PubMed ID: 8825614
[TBL] [Abstract][Full Text] [Related]
16. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.
Orendi JM; Bloem AC; Borleffs JC; Wijnholds FJ; de Vos NM; Nottet HS; Visser MR; Snippe H; Verhoef J; Boucher CA
J Infect Dis; 1998 Nov; 178(5):1279-87. PubMed ID: 9780247
[TBL] [Abstract][Full Text] [Related]
17. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
18. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens.
Ho HN; Hultin LE; Mitsuyasu RT; Matud JL; Hausner MA; Bockstoce D; Chou CC; O'Rourke S; Taylor JM; Giorgi JV
J Immunol; 1993 Apr; 150(7):3070-9. PubMed ID: 8454874
[TBL] [Abstract][Full Text] [Related]
19. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.
Larsen CS; Ostergård L; Møller BK; Buhl MR
Scand J Infect Dis; 2000; 32(2):153-60. PubMed ID: 10826900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
